文献速递系统性红斑狼疮

系统性红斑狼疮患者糖尿病风险:系统综述与荟萃分析

Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该系统综述与荟萃分析纳入37项研究共266537例系统性红斑狼疮患者,横断面研究与队列研究汇总分析均未显示系统性红斑狼疮患者糖尿病风险升高(OR=1.05,95%CI 0.87-1.27,P=0.63;RR=1.32,95%CI 0.93-1.87,P=0.12)。多项队列研究一致显示抗疟药可降低糖尿病风险,而糖皮质激素使用与糖尿病风险升高相关。

要点

  • 横断面与队列研究汇总均未显示系统性红斑狼疮患者糖尿病风险较对照升高。
  • 多项队列研究一致显示抗疟药与糖尿病风险降低相关。
  • 糖皮质激素使用与糖尿病风险升高相关,年龄、性别、高血压和免疫抑制剂未被识别为危险因素。

核心结论

  • 与对照相比,系统性红斑狼疮患者糖尿病风险未升高,但羟氯喹使用者或坚持用药者风险降低,糖皮质激素使用者风险升高。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、Cochrane Library和Web of Science自建库至2023年2月,纳入分析系统性红斑狼疮患者糖尿病风险的队列研究和横断面研究,共纳入37项研究(23项横断面研究、14项队列研究)涉及266537例系统性红斑狼疮患者,研究注册于PROSPERO(CRD42023402774)。

主要发现

  • 横断面研究汇总分析未显示系统性红斑狼疮患者糖尿病风险升高(OR=1.05,95%CI 0.87-1.27;P=0.63)。
  • 队列研究汇总分析未显示系统性红斑狼疮患者糖尿病风险升高(RR=1.32,95%CI 0.93-1.87;P=0.12)。
  • 多项队列研究一致显示抗疟药与糖尿病风险降低相关,糖皮质激素使用与糖尿病风险升高相关。
  • 年龄、性别、高血压和免疫抑制剂未被识别为系统性红斑狼疮患者糖尿病的危险因素。

关键数值与推荐

  • 横断面研究汇总OR=1.05(95%CI 0.87-1.27;P=0.63)。
  • 队列研究汇总RR=1.32(95%CI 0.93-1.87;P=0.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the risk of DM and evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE. METHODS: Electronic database searches of PubMed, Embase, Cochrane Library and Web of Science were performed from inception to February 2023. Cohort and cross-sectional studies that analysed the risk of DM in patients with SLE were included. The associations between diabetes and antirheumatic agents, such as antimalarials and glucocorticoids, were analysed in cohort studies. Data were pooled using fixed- or random-effects meta-analysis to estimate pooled odd ratios (OR), relative risks (RR) and 95% confidence intervals (CIs). This study was registered with PROSPERO (CRD42023402774). RESULTS: A total of 37 studies (23 cross-sectional and 14 cohort studies) involving 266 537 patients with SLE were included. The pooled analyses from cross-sectional studies and cohort studies did not show an increased risk of DM in SLE patients (OR = 1.05, 95% CI 0.87-1.27; P = 0.63 and RR = 1.32, 95% CI 0.93-1.87; P = 0.12, respectively). However, several cohort studies consistently demonstrated a reduced risk of diabetes with antimalarials, while glucocorticoid use has been associated with an increased risk of developing diabetes. Age, sex, hypertension and immunosuppressants have not been identified as risk factors for DM in SLE patients. CONCLUSION: Although there was no increased risk of DM in patients with SLE compared with controls, HCQ users or adherents had a decreased risk, whereas glucocorticoid users had an increased risk.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Etchegaray-Morales I, Mendoza-Pinto C, Munguía-Realpozo P, et al. Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis. Rheumatology (Oxford). 2024. PMID: 38552312. doi:10.1093/rheumatology/keae204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。